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Abstract
Arachidonic acid (AA), an essential polyunsaturated fatty acid, is one of the major components of neural membranes, 
which show an altered phospholipid composition in schizophrenia. Arachidonate 12-lipoxygenase (ALOX12), an 
important enzyme, metabolizes AA to 12-HPETE, which affects catecholamine synthesis. However, research has yet to 
show the genetic association between ALOX12 and schizophrenia. Therefore, we investigated single nucleotide 
polymorphisms (SNP) of the ALOX12 gene in schizophrenia, recruiting patients with schizophrenia (n = 289) and normal 
controls (n = 306) from a Korean population. We selected three SNPs (rs1126667, rs434473, and rs1042357) of the 
ALOX12 gene and genotyped them by direct sequencing. We reviewed the schizophrenic patients' medical records 
and assessed them clinically using the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Negative 
Symptoms (SANS), and the Operational Criteria Checklist (OPCRIT). Then we statistically analyzed the genetic 
associations between the SNPs and schizophrenia, finding a genetic association between both rs1126667 and 
rs1042357 and schizophrenia, in the recessive model (p = 0.015 and 0.015, respectively). We also found an association 
between rs434473 and negative symptoms, defined through a factor analysis of the OPCRIT data (p = 0.040). 
Consequently, we suggest that SNPs of the ALOX12 gene might be associated with schizophrenia and negative 
symptoms in this Korean population. These weak positives require additional study.
Findings
Essential polyunsaturated fatty acids (EPUFAs) are major
components of neural membranes. These membranes
show an altered composition in schizophrenia patients
[1]. Arachidonic acid (AA) and docosahexaenoic acid
(DHA) constitute 80-90% of EPUFAs in neuronal tissue,
but there is reduced AA in schizophrenia [2]. The
enzyme  ALOX12 oxygenates the C-12 of arachidonic
acid, producing 12-hydroperoxy-5, 8, 10, 14- eicosatetra-
enoic acid (12-HPETE) [3], which, research has shown,
inhibits protein kinase II [4]. Protein kinase II phospho-
rylates tyrosine hydroxylase, which is the rate-limiting
enzyme in catecholamine synthesis [5]. Accordingly, 12-
HPETE might affect dopamine synthesis. In addition, 12-
HPETE inhibits neurotransmitter release per se [6]. How-
ever, no research has yet shown the association between
ALOX12 and schizophrenia. Therefore, we hypothesized
genetic variances of the ALOX12 gene might be associ-
ated with schizophrenia. To test this hypothesis, we
investigated the single nucleotide polymorphisms (SNPs)
of the ALOX12 gene in schizophrenia patients.
We recruited patients meeting the Diagnostic and Sta-
tistical Manual of Mental Disorders, Fourth Edition
(DSM-IV) criteria for schizophrenia [7], resulting in a
study population consisting of 289 Korean patients with
schizophrenia [189 men and 100 women; age 42.85 ±
10.84 (mean ± S.D., in years)]. We also recruited 306
Korean control subjects (148 men and 158 women; age
36.06 ± 6.79). We reviewed the medical records of each
patient and assessed the schizophrenia patients using the
Brief Psychiatric Rating Scale (BPRS), the Scale for the
Assessment of Negative Symptoms (SANS), and the oper-
ational criteria (OPCRIT) checklist [8]. All studies were
carried out according to the guidelines of the Declaration
of Helsinki [9]. Written informed consent was obtained
from each subject, and the study was approved by the
Institutional Review Board of Kyung Hee University Hos-
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pital, Seoul, Republic of Korea. We selected three coding
SNPs with validated heterozygosity (>0.2; http://
www.ensembl.org, http://www.ncbi.nlm.nih.gov/SNP,
http://www.hapmap.org): coding region SNPs rs1126667,
rs434473, and rs1042357 (SNP database, BUILD 129,
Table 1). We used direct sequencing to conduct SNP
genotyping and amplified Genomic DNA was using the
following primers for each SNP: rs1126667 (sense, 5'-
TCAACTCAGAGAGGCCTTGAGAA-3'; antisense, 5'-
AAGTGAGGA AGTGCCATCAGGTG-3'; 622 bp),
rs434473 and rs1042357 (sense, 5'- CTCC TTCACAT-
TCCACCACCATC-3'; antisense, 5'- GTGAGTGAA-
GAGGAGACTGT CTC-3'; 625 bp). Then, we sequenced
the samples using an ABI Prism 377 automatic sequencer
(PE Applied Biosystems, Foster City, CA, USA) and ana-
lyzed sequence data using SeqMan II software (DNAS-
TAR Inc., Madison, WI, USA). The genotyping
completion rates of our samples were 96.4% (rs1126667),
95.0% (rs434473), and 98.1% (rs1042357). We excluded
samples with 1 or more misread or unreadable SNPs.
Therefore, 95.0% of the original samples were analyzed.
We analyzed Hardy-Weinberg equilibrium (HWE) and
genotype frequencies using SNPStats [10] and used mul-
tiple logistic regression models to calculate odds ratios
(OR), 95% confidence intervals (CI), and corresponding p
values; to control age and gender as covariables; and to
analyze the association between SNPs and schizophrenia.
T o  c a l c u l a t e  t h e  p o w e r  o f  t h e  s a m p l e  s i z e ,  w e  u s e d  a
genetic power calculator http://pngu.mgh.harvard.edu/
~purcell/gpc. In our case-control study, the powers were
0.8142 (rs1126667; effective sample size; number of cases
for 80% power = 292), 0.8105 (rs434473, n = 292), and
0.8141 (rs1042357, n = 296). However, the sample power
in subgroup-divided schizophrenia was not sufficient
(data not shown). We also tested clinical variables,
including OPCRIT checklist data. The significance level
for all statistical tests was 0.05, and we applied Bonferroni
corrections for multiple tests in the association study
(number of tests = 18).
We found no deviation from the Hardy-Weinberg equi-
librium for the selected SNPs. The SNPs rs1126667 and
rs1042357 showed significant associations in the reces-
sive model after Bonferroni correction (p = 0.015, OR =
1.60, 95% CI = 1.09-2.35; p = 0.015, OR = 1.60, 95% CI =
1.09-2.35, Table 1). We found no genetic association with
gender, schizophrenia subtypes, BPRS, SANS, or any of
the OPCRIT items. However, when we categorized the
OPCRIT items into four symptom subgroups (excite-
ment, negative symptoms, hallucinations, and delusions)
by factor analysis, we found an association between
rs434473 and the negative symptom subgroup (Table 2).
While our genetic data is statistically significant, the p
values of our data are only weakly positive. We character-
ized the LD block between the three ALOX12 SNPs in the
total subjects, using the pairwise D' values (Figure 1). The
D' values from rs4730775 to rs32024233 and from
rs37795488 to rs17132543 ranged over 0.99, indicating a
strong LD between each pair of markers (Figure 1). This
revealed an LD block, comprised of rs1126667, rs434473,
and rs1042357.
Lipoxygenases are non-heme iron dioxygenase
enzymes that insert molecular oxygen into free and ester-







Model OR 95% CI p
Freq. % Freq. % LCL UCL
rs1126667 R261Q G/G 96 31.4 77 26.6 Codominant 1.09 0.75 1.59 0.048
(Exon 6) A/G 151 49.4 132 45.7 Dominant 1.26 0.88 1.80 0.200
A/A 59 19.3 80 27.7 Recessive 1.60 1.09 2.35 0.015*
rs434473 S322N A/A 96 31.4 78 27.0 Codominant 1.09 0.74 1.58 0.073
(Exon 8) A/G 153 50.0 135 46.7 Dominant 1.24 0.87 1.76 0.240
G/G 57 18.6 76 26.3 Recessive 1.56 1.06 2.30 0.025*
rs1042357 T364T C/C 95 31.1 77 26.6 Codominant 1.07 0.73 1.57 0.050*
(Exon 8) A/C 152 49.7 132 45.7 Dominant 1.24 0.87 1.77 0.240
A/A 59 19.3 80 27.7 Recessive 1.60 1.09 2.35 0.015*
ALOX12, arachidonate 12-lipoxygenase; R, arginine; Q, glutamine; S, serine; N, asparagine; T, threonine; Freq, frequency; OR, odds ratio; CI, 
confidence interval; LCL, lower confidence limit; UCL, upper confidence limit; p, probability value.
*These values are not significant after the Bonferroni correction (number of tests = 18).Kim et al. Behavioral and Brain Functions 2010, 6:44
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ified polyunsaturated fatty acids [11]. Research has sug-
gested that ALOX12 might be involved with
neurodegeneration [12]. Pratico et al. [13] showed that
ALOX12 is higher in Alzheimer's disease, suggesting that
it correlates with brain oxidative stress. In our data,
rs1126667 and rs1042357 showed associations with
schizophrenia in the recessive model. A/A carriers of
rs1126667 and A/A carriers of rs1042357 had signifi-
cantly higher odds ratios, of 1.60 (95% CI = 1.09-2.35), for
schizophrenia. The SNP rs1126667 is a missense SNP
that substitutes glutamine for arginine at amino acid
position 261. This SNP is located in the lipoxygenase
domain (amino acid position: from 124 to 655) in the
ALOX12 protein. However, no research has yet shown a
functional change in catalytic ability due to rs1126667.
Although rs1042357 is synonymous, it can make an
exonic splicing enhancer (5'- AGAAGC-3' and 5'-
CAGAAG-3') with its A allele, whereas its C allele does
not make one (genes.mit.edu/burgelab/rescue-ese). Thus,
the A allele of rs1042357 in the lipoxygenase domain of
the ALOX12 protein may lead to inaccurate splicing of
pre-mRNA of the ALOX12 gene, which can produce an
abnormal ALOX12 enzyme. In addition, rs434473 was
associated with the negative symptom subgroup in
OPCRIT items, which comprise slower activity, loss of
energy/tiredness, loss of pleasure, and diminished libido
(Table 2). There is evidence that 12-HPETE, the metabo-
lite of arachidonate made by ALOX12 correlates with
synthesis of catecholamine. High 12-HPETE inhibits pro-
tein kinase II [4]. In addition, research has shown protein
kinase II is responsible for the phosphorylation of
tyrosine hydroxylase, which is the rate-limiting step in
Table 2: Genotype distribution of ALOX12 gene SNPs among schizophrenia patients in a Korean population.
SNP Amino acid Genotype Negative† (+) N = 168 Negative† (-) N = 121 χ2 df P
Freq. % Freq. %
rs1126667 R261Q G/G 41 24.4 36 29.8
(Exon 6) A/G 86 51.2 46 38.0 4.984 2 0.083
A / A4 12 4 . 43 93 2 . 2
rs434473 S322N A/A 41 24.4 37 30.6
(Exon 8) A/G 89 53.0 46 38.0 6.428 2 0.040*
G / G3 82 2 . 63 83 1 . 4
rs1042357 T364T C/C 41 24.4 36 29.8
(Exon 8) A/C 86 51.2 46 38.0 4.984 2 0.083
A / A4 12 4 . 43 93 2 . 2
ALOX12, arachidonate 12-lipoxygenase; R, arginine; Q, glutamine; S, serine; N, asparagine; T, threonine; Freq, frequency; df, degree of freedom; p, 
probability value.
*The value is not significant after the Bonferroni correction (number of test = 18).
†Negative symptom subgroup identified by factor analysis of OPCRIT data.
Figure 1 Linkage disequilibrium (LD) block of ALOX12 gene. LD 
coefficient (|D'|) and LD blocks among ALOX12 SNPs. Block consists of 
rs1126667, rs434473, and rs1042357.Kim et al. Behavioral and Brain Functions 2010, 6:44
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the synthesis of (something is missing) [5]. The relatively
less-phosphorylated tyrosine hydroxylase leads to
reduced dopamine levels. In addition, 12-HPETE inhibits
neurotransmitter release [6]. Thus, hypodopaminergia
caused by decreased synthesis and release of dopamine
might be present in deficit schizophrenia [14]. ALOX12
has been studied in connection with various malignan-
cies, including colorectal cancer [11,12,15], breast cancer
[16,17], prostate cancer [18-20], bladder cancer [21], and
testicular cancer [22]. Research has shown that schizo-
phrenia patients have an increased malignancy risk
regarding colon cancer, marginally increased risk of
breast cancer, and decreased risk of respiratory cancer
[23]. ALOX12 might be one of the factors explaining the
high risk of colorectal cancer in patients with schizophre-
nia. Thus, the relationship between ALOX12 and the
higher incidence of colorectal cancer in schizophrenia
patients needs future study. We conclude that rs1126667
and rs1042357 of the ALOX12 gene correlate with
schizophrenia in a Korean population, and rs434473 cor-
relates with negative symptoms in schizophrenia. These
weak positives require additional replication study. These
results suggest that future studies should regard ALOX12
as an important gene in the pathology of schizophrenia.
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